RCUS Arcus Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NYSE: RCUS

Price (delayed)

$24.9

Market cap

$3.13B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.19

Enterprise value

$3.03B

?
Relative Growth: Rel. Growth: 59
Relative Strength: Rel. Strength: 85
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 34

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. ...

Highlights
RCUS's EPS is up by 24% year-on-year and by 3% since the previous quarter
The gross profit has soared by 67% YoY but it has contracted by 4.5% from the previous quarter
RCUS's revenue has soared by 67% YoY but it is down by 4.5% QoQ
Arcus Biosciences's debt has soared by 108% YoY
RCUS's quick ratio is down by 25% year-on-year and by 8% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.arcusbio.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of RCUS

RCUS stock price

How has the Arcus Biosciences stock price performed over time
Intraday
4.36%
1 week
1.72%
1 month
-4.41%
1 year
159.38%
YTD
4.49%
QTD
15.28%

Financial performance

How have Arcus Biosciences's revenue and profit performed over time
Revenue
$236M
Gross profit
$236M
Operating income
-$398M
Net income
-$369M
Gross margin
100%
Net margin
-156.4%
The gross profit has soared by 67% YoY but it has contracted by 4.5% from the previous quarter
RCUS's revenue has soared by 67% YoY but it is down by 4.5% QoQ
The operating margin has increased by 45% year-on-year but it has declined by 8% since the previous quarter
Arcus Biosciences's net margin has increased by 44% YoY but it has decreased by 9% from the previous quarter

Price vs fundamentals

How does RCUS's price correlate with its fundamentals

Growth

What is Arcus Biosciences's growth rate over time

Valuation

What is Arcus Biosciences stock price valuation
P/E
N/A
P/B
5.96
P/S
13.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.84
RCUS's EPS is up by 24% year-on-year and by 3% since the previous quarter
RCUS's price to book (P/B) is 97% higher than its 5-year quarterly average of 2.9 and 63% higher than its last 4 quarters average of 3.5
RCUS's equity is down by 17% since the previous quarter
RCUS's revenue has soared by 67% YoY but it is down by 4.5% QoQ
RCUS's P/S is 63% above its last 4 quarters average of 7.8 and 12% above its 5-year quarterly average of 11.3

Efficiency

How efficient is Arcus Biosciences business performance
RCUS's return on sales is up by 44% year-on-year but it is down by 9% since the previous quarter
RCUS's ROIC is down by 12% YoY and by 9% from the previous quarter
Arcus Biosciences's return on assets has decreased by 9% QoQ and by 7% YoY
The return on equity has declined by 4.9% since the previous quarter but it has increased by 2.3% year-on-year

Dividends

What is RCUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RCUS.

Financial health

How did Arcus Biosciences financials performed over time
The total assets is 111% greater than the total liabilities
RCUS's current ratio is down by 25% YoY and by 7% from the previous quarter
RCUS's quick ratio is down by 25% year-on-year and by 8% since the previous quarter
Arcus Biosciences's debt is 81% less than its equity
RCUS's debt to equity has surged by 111% year-on-year and by 19% since the previous quarter
Arcus Biosciences's debt has soared by 108% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.